Our Story

We launched Fulcrum Therapeutics with a bold vision: To change the course of genetically defined diseases by treating them at their root cause.

Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively about the best way to modulate and balance gene expression. The result: FulcrumSeek, a patient-focused product engine designed to systematically identify high-value, de-risked targets at speed and scale for rare genetic diseases. We take great pride in being purposeful patient partners who do this work, not just for patients, but with patients. We have a culture of trust and transparency which enables our employees to focus on our mission and the science behind it. In addition, we are invested in our people and want to ensure they have the tools and training they need to succeed. This allows our playful spirit to come alive, making work more enjoyable for our entire Fulcrew.

Bryan Stuart

Bryan Stuart

President and Chief Executive Officer, Board Member
Bryan Stuart was named president and chief executive officer of Fulcrum Therapeutics in March 2021. He joined Fulcrum as chief operating officer in 2018, bringing over 20 years of industry experience, predominantly in the rare disease space. He has played a leadership role in advancing numerous rare disease programs from the clinic to commercialization. Prior to joining Fulcrum, Bryan was president and CEO of Yarra Therapeutics, a subsidiary of Array BioPharma focused on genetically defined rare diseases. He also served as president and then CEO of Kastle Therapeutics, a biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases. Prior to Kastle, Bryan was chief business officer of Civitas Therapeutics, where he led the business development, capital raising, commercial and portfolio management functions including a planned IPO and eventual sale of the company to Acorda Therapeutics. He also led business development, corporate development and strategy at EKR Therapeutics (acquired by Chiesi) and Ovation Pharmaceuticals (acquired by Lundbeck A/S), where he played key roles in the successful sales of both companies. Bryan began his career as a healthcare investment banker at William Blair & Company. He has an MBA from the Kellogg School at Northwestern University and a bachelor’s degree from the University of Illinois.[/amoteam_text]
Mel Hayes

Mel Hayes

Chief Operating Officer

Mel Hayes joined Fulcrum Therapeutics in September 2021 as chief commercial officer, bringing more than 25 years of experience in development and management of commercialization strategies in a range of therapeutic areas including many rare and specialty diseases. At Fulcrum he is responsible for leading the company’s commercial strategies and operations, including marketing, sales, new product planning, business analytics, and patient engagement. Prior to Fulcrum, Mr. Hayes most recently served as global head commercial, vice president, rare blood disorders at Sanofi-Genzyme, where he led the commercial organization for hemophilia and complement assets. He also served as U.S. vice president hemophilia and global head, hematology rare blood disorders at Bioverativ (acquired by Sanofi-Genzyme). He was formerly global vice president, head of global marketing and launch excellence at Shire and was global vice president hemophilia at Baxalta (acquired by Shire). He also spent 10 years at Bayer and nine years at Bristol Myers Squibb in progressive leadership roles where he was responsible for launching products in diabetes, cardiovascular disease, neurology, rheumatology, multiple sclerosis and Parkinson’s disease. He earned dual bachelor’s degrees in business and communications from Southern Methodist University and an MBA from Columbia University.

Esther Rajavelu

Esther Rajavelu

Chief Financial Officer

Esther Rajavelu joined Fulcrum in January 2022 as chief financial officer, bringing nearly 20 years of experience in the life sciences sector spanning equities research, investment banking and strategic consulting. She was previously a senior equities research analyst at UBS Securities covering small-cap and mid-cap biotechnology companies. She also covered biotechnology and pharmaceutical companies as an analyst at Deutsche Bank and Oppenheimer & Co. Prior to her career in equities research, she spent several years as an investment banker focused on life sciences companies at leading financial institutions including Bank of America Merrill Lynch and EY Capital Advisors. Esther began her career as a pharmaceuticals strategy consultant. She earned a bachelor’s degree in economics and international relations from Wesleyan University and an MBA from the Wharton School of the University of Pennsylvania.

Curtis Oltmans, JD

Curtis Oltmans, JD

Chief Legal Officer

Curtis Oltmans, JD joined Fulcrum as General Counsel in November 2020 with over 25 years of experience in
corporate law including senior management positions in legal departments at several leading
pharmaceutical and biotechnology companies. He most recently served as Vice President, Head of
Litigation at DaVita Kidney Care, Inc. where he led a 30-person team and was responsible for all
litigation, workers’ compensation and employee safety matters. Prior to DaVita, Curtis was Executive
Vice President, General Counsel and Corporate Secretary at Array BioPharma Inc. where he oversaw all
legal, corporate governance, patent and compliance matters. He previously served as Corporate Vice
President and General Counsel for Novo Nordisk, Inc., North America where he was responsible for
strategic support in areas including market access, government affairs, communications and product
marketing. He has also served as Assistant General Counsel for Eli Lilly and Company after beginning his
legal career supporting clients in pharmaceutical and medical device litigation matters. Curtis received a
BA in political science from the University of Nebraska and his JD from the University of Nebraska
College of Law.

Kim Hazen

Kim Hazen

Chief People Officer
Kim Hazen joined Fulcrum in September 2017 with over 25 years of experience in human resources. Most recently, she was vice president of human resources at Warp Drive Bio, where she led efforts to build a drug discovery culture and core values to match with an emphasis on elite performance. Prior to joining Fulcrum and Warp Drive Bio, Kim served as the executive director of human resources at Aegerion Pharmaceuticals and as head of human resources at the Broad Institute of MIT and Harvard. Before joining the life sciences industry, she worked on the investment side of human resources at Pioneer Investments, Fidelity Investments, Liberty Mutual and Bank of America. Kim received a bachelor’s in psychology from SUNY Potsdam and her MBA from Boston University.[/amoteam_text]
Mani Sundararajan, Ph.D.

Mani Sundararajan, Ph.D.

Senior Vice President, Technical Operations
Mani Sundararajan, Ph.D., joined Fulcrum in July 2021 as senior vice president, technical operations. Most recently he worked at Seagen, where he led several technical operations functions including small molecules process development, CMC strategy and program management. He has also held leadership positions in drug development and technical operations at Takeda, Shire, AstraZeneca, Bristol-Myers Squibb and DuPont Pharmaceuticals. Mani has a B.Sc.(Tech.) in pharmaceuticals & fine chemicals technology from the Institute of Chemical Technology at University of Mumbai, India, an M.S. and Ph.D. in pharmaceutical sciences from Temple University, and an executive masters in technology management from University of Pennsylvania’s School of Engineering & Applied Science and Wharton.
Paul Bruno, Ph.D.

Paul Bruno, Ph.D.

Senior Vice President, Business and Corporate Development

Paul Bruno, Ph.D., was named Senior Vice President, Business and Corporate Development in August 2022, bringing experience in business development, corporate development, strategic consulting, and R&D. He joined Fulcrum in 2019 where he has held various roles related to business and corporate development. He was previously at ClearView Healthcare Partners, a life sciences strategy firm that specializes working with biotech, pharma, and medtech companies. At ClearView, Paul worked with clients on engagements related to corporate strategy, portfolio management, pipeline prioritization, and business development. Paul completed a postdoctoral fellowship at Boston Children’s Hospital where he focused on identifying fetal hemoglobin inducers for sickle cell disease and β-thalassemia. He also brings entrepreneurial experience, having previously co-founded and raised seed funding for an early-stage materials company. He received his PhD in chemistry from the University of Michigan and a BS from Santa Clara University where he double majored in chemistry and public health.

Santiago Arroyo, M.D., Ph.D.

Chief Medical Officer

Dr. Arroyo brings to Fulcrum nearly 20 years of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease areas. In his role as Chief Medical Officer at Momenta Pharmaceuticals (acquired by Johnson & Johnson), Dr. Arroyo led the clinical development of the company’s broad portfolio of hematology, neurology, immunology, and materno-fetal therapeutics. Previously, he was the Chief Medical Officer of Boston Pharmaceuticals. Before that, he held multiple clinical roles at Bristol-Myers Squibb and Pfizer, where he was the Head of Clinical Research and Chief Medical Officer for Pharmacotherapeutics. Earlier, Dr. Arroyo held clinical development roles at Eisai Global Clinical Development and Schwarz Biosciences. Dr. Arroyo began his career as an academic neurologist at the Medical College of Wisconsin, Johns Hopkins Hospital and Medical School, and the Hospital Clinic de Barcelona in Spain. He earned a Ph.D. from the Universidad de Barcelona and an M.D. from the Universidad Autonóma de Madrid.